NMPA clears Ph 3 study of mesutoclax (ICP-248) + azacitidine versus venetoclax with azacitidine in elderly or unfit 1L AML patients
Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, said, “The efficacy and safety mesutoclax has demonstrated to date give us the confidence to test it head-to-head against the global standard of care. Mesutoclax is one of our key global assets. We have been accelerating the global trial of mesutoclax in combination with azacitidine for AML, with patients enrolled in the U.S. and Australia. We will further advance its clinical development to bring this innovative therapy to more patients worldwide as early as possible.”
Share:
More News
“Completing enrollment in the Phase III TIGeR-PaC trial marks a major milestone for RenovoRx,” said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. “TIGeR-PaC is the cornerstone of our clinical development program, and we are now closer than ever in our efforts to validate IAG and
“Zipalertinib is a compound created through Taiho Pharmaceutical’s proprietary drug discovery technology,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “Achieving positive results in this Phase 3 trial in the first-line setting represents an important milestone for this program. We will continue to work closely with Taiho Oncology
“We are pleased to welcome C-CAR039 back to our hematology malignancy portfolio,” said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. “Clinical trial results to date have demonstrated the favorable safety and encouraging efficacy of C-CAR039 in r/r LBCL patients. We believe that it has potential to help
“We are delighted to transform our discoveries in glioblastoma into a promising new vaccine program with EVX-05, which could hold a significant therapeutic potential in area of massive unmet medical need. We have an outstanding collaboration with Duke University and now see the huge benefits of combining their extensive disease